BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6400
- TODAY'S CHANGE (%)-0.0279 (-4.1773%)
- Bid / Lots0.6261/ 1
- Ask / Lots0.6400/ 5
- Open / Previous Close0.6590 / 0.6679
- Day Range
- 52 Week Range
- Volume195,898
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 6892 | 0.659 |
| 09:38 ET | 10281 | 0.6406 |
| 09:41 ET | 502 | 0.646 |
| 09:43 ET | 2600 | 0.6417 |
| 09:45 ET | 100 | 0.65 |
| 09:48 ET | 2196 | 0.6476 |
| 09:50 ET | 267 | 0.65 |
| 10:01 ET | 642 | 0.65 |
| 10:10 ET | 5800 | 0.6452 |
| 10:12 ET | 29078 | 0.64 |
| 10:15 ET | 250 | 0.645 |
| 10:19 ET | 8900 | 0.64 |
| 10:28 ET | 180 | 0.640761 |
| 10:30 ET | 100 | 0.64 |
| 10:33 ET | 100 | 0.6498 |
| 10:37 ET | 1500 | 0.644899 |
| 10:39 ET | 2000 | 0.64 |
| 10:44 ET | 1300 | 0.6449 |
| 10:46 ET | 2600 | 0.6497 |
| 10:50 ET | 1700 | 0.64 |
| 11:02 ET | 1700 | 0.64 |
| 11:26 ET | 100 | 0.6447 |
| 11:31 ET | 650 | 0.6402 |
| 11:38 ET | 500 | 0.649299 |
| 11:40 ET | 485 | 0.6402 |
| 11:42 ET | 100 | 0.64 |
| 12:21 ET | 5300 | 0.641 |
| 12:25 ET | 900 | 0.6485 |
| 12:27 ET | 312 | 0.6488 |
| 12:30 ET | 300 | 0.6489 |
| 12:36 ET | 5000 | 0.6488 |
| 12:59 ET | 135 | 0.641001 |
| 01:01 ET | 100 | 0.6486 |
| 01:17 ET | 1300 | 0.641 |
| 01:26 ET | 100 | 0.648399 |
| 01:32 ET | 2950 | 0.6405 |
| 01:37 ET | 3248 | 0.6409 |
| 01:39 ET | 300 | 0.6396 |
| 01:44 ET | 150 | 0.6402 |
| 01:48 ET | 12923 | 0.6409 |
| 02:02 ET | 100 | 0.6409 |
| 02:15 ET | 2222 | 0.635 |
| 02:18 ET | 200 | 0.6334 |
| 02:24 ET | 10050 | 0.631 |
| 02:26 ET | 4000 | 0.6309 |
| 02:27 ET | 6300 | 0.63 |
| 02:29 ET | 4650 | 0.63 |
| 02:31 ET | 5900 | 0.6307 |
| 02:38 ET | 3400 | 0.6307 |
| 02:40 ET | 792 | 0.6332 |
| 02:42 ET | 200 | 0.6332 |
| 02:49 ET | 215 | 0.64 |
| 03:03 ET | 1300 | 0.6336 |
| 03:05 ET | 2201 | 0.634 |
| 03:16 ET | 12994 | 0.63 |
| 03:27 ET | 1000 | 0.6316 |
| 03:30 ET | 680 | 0.6328 |
| 03:34 ET | 100 | 0.6316 |
| 03:38 ET | 400 | 0.632799 |
| 03:41 ET | 954 | 0.63155 |
| 03:45 ET | 670 | 0.6316 |
| 03:54 ET | 300 | 0.6316 |
| 03:56 ET | 792 | 0.6324 |
| 03:57 ET | 600 | 0.6328 |
| 03:59 ET | 17772 | 0.64 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 55.9M | -0.8x | --- |
Cue Biopharma Inc | 66.2M | -1.3x | --- |
Dyadic International Inc | 60.8M | -7.2x | --- |
Lipocine Inc | 50.8M | -6.3x | --- |
LAVA Therapeutics NV | 61.5M | -2.0x | --- |
Kronos Bio Inc | 64.9M | -0.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $55.9M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
